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The Hierarchical Taxonomy of Psychopathology (HiTOP) is an empirical structural model of psychological symptoms 
formulated to improve the reliability and validity of clinical assessment. Neurobiology can inform assessments of early 
risk and intervention strategies, and the HiTOP model has greater potential to interface with neurobiological measures 
than traditional categorical diagnoses given its enhanced reliability. However, one complication is that observed 
biological correlates of clinical symptoms can reflect various factors, ranging from dispositional risk to consequences of 
psychopathology. In this paper, we argue that the HiTOP model provides an optimized framework for conducting research 
on the biological correlates of psychopathology from an ontogenetic perspective that distinguishes among indicators of 
liability, current symptoms, and consequences of illness. Through this approach, neurobiological research can contribute 
more effectively to identifying individuals at high dispositional risk, indexing treatment-related gains, and monitoring the 
consequences of mental illness, consistent with the aims of the HiTOP framework.
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Introduction
The Hierarchical Taxonomy of Psychopathology (HiTOP1,2) 
was advanced to characterize the empirical structure of 
psychopathology and overcome the myriad problems 
inherent in consensus-based nosologies such as the Diag-
nostic and Statistical Manual of Mental Disorders (DSM).3 
The HiTOP model, which is derived from factor-analytic 
studies of symptoms, diagnoses, and maladaptive trait data, 
describes a hierarchy of continuous dimensions accounting 
for broader spectra and super-spectra as well as narrower, 
symptom-level manifestations of psychopathology (Figure 
1). For example, the Internalizing spectrum encompasses 
narrower subfactors including Fear and Distress, which, 
in turn, encompass even more specific clinical phenotypes 
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the HiTOP framework is that continuous symptom dimen-
sions exhibit higher reliabilities than categorical diagnoses,4 
laying the foundation for more valid measurement of 
psychopathology.1,5 Other strengths include the capacity of 
a dimensional approach to accommodate the heterogeneity 
of diagnostic conditions and their systematic co-occurrence. 
For example, high rates of comorbidity between DSM-de-
fined generalized anxiety disorder and major depressive 
disorder—themselves highly heterogeneous syndromes—
are likely to reflect cognitive, behavioral, and neurobiolog-
ical commonalities between the two. Within HiTOP, these 
shared features are reflected in the Distress subfactor, with 
traits and symptoms specific to one or the other syndrome 
represented at lower levels of the hierarchy. Each level is 
conceptualized as a continuous dimension from minimal 
to extreme severity, rather than coded as absence versus 
presence of that feature. This structure facilitates the linkage 
of both broader and more specific HiTOP dimensions, iden-
tified through self-, peer, and clinician report, to variation 
observed in other measurement modalities (eg, functional 
neuroimaging) as a way to better understand psychobiolog-
ical systems contributing to both transdiagnostic and condi-
tion-specific aspects of psychopathology.6 In this respect, 
the HiTOP approach is consistent with the National Insti-
tute of Mental Health’s Research Domain Criteria (RDoC) 
initiative.7
HiTOP’s emphasis on transdiagnostic common factors 
contrasts with the recent Addictions Neuroclinical Assess-
ment (ANA8,9) framework, which attempts to use neurobi-
ology to address heterogeneity within a single phenomenon 
(ie, addiction), failing to consider that many neural indicators 
may operate transdiagnostically. The hierarchical structure of 
HiTOP provides a framework for more systematically 
investigating common and specific etiological processes 
in psychopathology using neurobiological methods and 
measures.6
Improved measurement of manifest symptomatology, as 
represented in the HiTOP framework, provides an unprec-
edented opportunity to elucidate the ontogeny of mental 
illness—the developmental-experiential processes that, over 
time, give rise to psychopathology and its consequences.10 
A deeper, developmentally informed understanding of the 
mechanisms and processes that contribute to the range of 
known psychological problems would contribute directly 
and importantly to prevention and intervention efforts,11 
consistent with calls by psychiatrists for transdiagnostic 
“staging models” of psychopathology.12 The goal of the 
present paper is to describe an ontogenetic framework for 
continuing research on the emergence, progression, and 
persistence of psychopathology in the context of the HiTOP 
framework. In doing so, we argue for the utility of neural 
systems variables alongside experiential and behavioral 
descriptions in characterizing these pathways.6,13,14
Importantly, however, we also highlight distinctions in the 
role neurobiology is expected to play at different points 
in the ontogeny of psychopathology. For example, neural 
indicators of latent liability for psychopathology need to be 
distinguished from those reflecting symptoms and conse-
quences of clinical illness. The ANA and similar initiatives 
do not specifically address this critical point, and it remains 
unclear what aspects of substance addiction are indexed by 
variables they identify as relevant neural indicators. This 
muddled picture is likely to impede the development of 
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effective interventions. Differences among latent liability, 
current symptomatology, and consequences of psycho-
pathology warrant strong consideration in the search for 
biological indicators of mental illness.
The HiTOP framework, too, can benefit from a formalized 
ontogenetic model of psychopathology. The current focus of 
HiTOP is on the most clinically salient point of this progres-
sion—ie, current manifest symptomatology. However, 
it cannot be assumed—indeed, it seems unlikely—that 
biological correlates of manifest symptom dimensions 
represented at various levels of the HiTOP hierarchy 
will necessarily reflect etiological mechanisms contrib-
uting to these dimensions. The HiTOP model is descrip-
tive, providing important information about the empirical 
structure of psychopathology and points of observed co- 
occurrence versus distinctiveness of symptoms, with major 
implications for nosological refinement. Building upon the 
model as it stands, the ontogenetic synthesis presented here 
is intended to more clearly explicate the temporal and etio-
logical aspects of psychopathology. From this perspective, 
a systematic, developmentally oriented program of research 
is needed to characterize the nature of biological processes 
that are relevant to various stages in the progression from 
latent liability to active psychopathology and its conse-
quences.
The basic form of the proposed ontogenetic framework for 
psychopathology is depicted in Figure 2. Each element of 
the framework is discussed in further detail below with 
reference to the running example of substance problems, 
as well as other syndromes where space allows. Briefly, 
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Figure 1. The Hierarchical Taxonomy of Psychopathology (HiTOP). Recent efforts by an international consortium of  
researchers have produced this hierarchical, dimensional system for organizing psychological symptoms (https://medicine.
stonybrookmedicine.edu/HITOP/). Figure depicts a simplified schematic of the HiTOP working model.1 Constructs toward  
the top are broader and more general, whereas those shown lower in the figure are narrower and more specific. HiTOP is  
a work in progress and will be updated on the basis of new data. Dashed lines indicate provisional elements requiring more 
study. Categorical disorder constructs are included to allow mapping of existing nosologies onto HiTOP, and those with the 
most prominent cross-loadings are listed in multiple places. Minus sign indicates negative association between histrionic 
personality and the detachment spectrum. Adapted with permission from ref 1: Kotov R, Krueger RF, Watson D, et al. The 
Hierarchical Taxonomy of Psychopathology (HiTOP): a dimensional alternative to traditional nosologies. J Abnorm Psychol. 
2017;126:454-477. Copyright ©2017 American Psychological Association.
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the model defines liability factors as premorbid, transdi-
agnostic individual-difference characteristics conducive to 
psychopathology. These risk factors are presumed to reflect 
genetically influenced neural and cognitive processes, as 
well as early childhood experiences such as maltreatment 
or fetal alcohol exposure, that create a context for the oper-
ation of experiential influences on psychological processes 
and behavior.15 The delineation of dispositional charac-
teristics that prospectively predict psychopathology can 
help to identify individuals in greatest need of preventive 
efforts and those likely to be most amenable to particular 
treatments.
The second part of the model depicted in Figure 2 consists 
of current symptomatology—that is, the presence of 
thoughts, feelings, and behaviors that are associated with 
some degree of distress and/or impairment, and the neural 
indicators that covary with them over time. (While distress 
and impairment criteria are ubiquitous in current nosolog-
ical frameworks of mental illness, discussion is ongoing 
about the exact manner in which distress and impairment 
are modeled within HiTOP.16) Within the ontogenetic 
model, current symptoms are conceptualized as products 
of the complex interplay of liabilities and experience in 
promoting a particular manifestation of psychopathology. 
This stage of the ontogenetic progression corresponds to 
the symptom dimensions represented in HiTOP, which 
vary continuously in severity—rather than dichotomously 
as presence versus absence of particular features. In contrast 
with the relative stability of liability factors, current symp-
tomatology and its associated neural indicators are expected 
to fluctuate over time, and thus can be used to monitor 
therapy-related improvements.
Finally, consequences of psychopathology encompass the 
lasting psychological and neurobiological alterations that 
are caused by mental illness and persist despite fluctuations 
in symptom expression. Of particular interest in this ontoge-
netic model are the structural and functional neural abnor-
malities caused by episodes of mental illness, consistent 
with a “scar model.”17 “Scarring” differs from current symp-
tomatology in that it is maintained regardless of improve-
Figure 2. Schematic of the ontogenetic model of psychopathology. Double-headed arrows connecting manifest symptoms 
and concomitant neural indicators reflect correspondence between them. Single-headed diagonal arrows represent  
prospective prediction of changes in symptomatology by current neural indicators.
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ment in symptoms. Consequences of psychopathology play 
an important role in the ontogenetic pathway because they 
can be used to monitor the progression of a syndrome in 
terms of persisting effects on the brain and behavior.
Liability and its neural indicators
Within the ontogenetic framework, liability factors can be 
defined as genetically influenced dispositions, susceptible 
to early environmental modulation, that are associated 
with risk for psychopathology prior to the onset of illness. 
The identification of liability factors is a crucial research 
priority, as they serve as the basis for investigating how 
distal, heritable dispositions intersect with and contribute to 
more proximal pathogenic processes to give rise to mani-
fest psychopathology.18 Further, research on latent liability 
factors and their manifestations across particular measure-
ment modalities (eg, specific patterns of neural response; 
Figure 3) can allow for the identification of individuals most 
likely to exhibit later psychopathology, so they can be prior-
itized for prevention programs. Knowledge of an individ-
ual’s constellation of liability factors could also be used to 
predict the efficacy of particular intervention approaches 
and thereby guide treatment planning.
Different strategies can be used to identify indicators of 
liability and establish their prognostic efficacy (Figure 4). 
The first and most crucial is to conduct longitudinal studies 
of young people exhibiting a candidate liability indicator to 
determine whether it prospectively predicts the emergence of 
the expected form of psychopathology. For example, longi-
tudinal studies have identified indicators that are informative 
about the future likelihood of developing substance problems 
(SPs) and the probable course of such problems. Of note, 
although initially aimed at specific SPs such as alcohol or 
cocaine use disorder, numerous studies over the past several 
decades suggest that the most robust indicators of SP liability 
reflect risk for externalizing problems more broadly.19-21 The 
implication is that these indicators operate at higher levels 
of the HiTOP system (ie, the Disinhibited Externalizing 
spectrum or Externalizing super-spectrum.) (Although not 
visually depicted in the original HiTOP model [Figure 1], 
the Externalizing super-spectrum is conceptualized as encom-
passing the Disinhibited Externalizing and Antagonistic 
Externalizing spectra). HiTOP-aligned research can facilitate 
efficient discovery of such principles by attending to multiple 
levels of the hierarchy simultaneously, rather than requiring 
decades of research on clinical groups segregated by diag-
nosis to reach the same conclusion.
Figure 3. Depiction of the relation of liability to its indicators. Here, liability is conceptualized as a latent (unobservable)  
predisposition to some form of psychopathology (eg, externalizing problems). This latent factor can be operationalized and 
measured through observable indicators from different modalities, including neural (eg, blunted target-P3 response), behav-
ioral (eg, lower accuracy on an executive function task), and report-based indicators (eg, higher scores on a questionnaire 
assessing disinhibition). See ref 37 for further discussion of the relations between latent constructs and observable indicators.
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One example of a well-established neural indicator of 
liability for SPs and other externalizing conditions is the 
target-P3 event-related potential (ERP), a brain response 
elicited by infrequently occurring task stimuli requiring a 
response. The P3 is thought to reflect cognitive processing 
following stimulus events,19 and it covaries positively with 
task measures of executive function.20 Research beginning 
in the 1980s found blunted amplitude of the target-P3 ERP 
response to be consistently linked to SPs,22-24 with later 
research extending this finding to individuals with exter-
nalizing problems of other types.19,25-27 Blunted target-P3 
was also observed in clinically unaffected relatives of indi-
viduals with externalizing problems, such as children of 
parents with SPs,28-30 and twin studies revealed a substan-
tial contribution of genetic influences to target-P3 ampli-
tude (Figure 5).31 Building on these findings, Iacono and 
colleagues28 demonstrated that blunted target-P3 in adoles-
cence predicted subsequent development of SPs and other 
externalizing problems in adulthood. The prospective nature 
of this association, together with evidence for familial 
aggregation, suggests that blunted target-P3 response, as 
a reflection of diminished cognitive processing of task- 
relevant stimuli, may constitute an indicator of liability for 
externalizing psychopathology (Figure 4).
Another key approach to evaluating candidate liability 
indicators is to quantify genetic influences on an indi-
cator variable’s association with psychopathology using 
multivariate causal modeling in twin studies. A substantial 
genetic contribution to the observed covariance between 
a putative liability indicator and an outcome measure of 
psychopathology implicates the presence of a common 
genetic predisposition in both. In conjunction with longi-
tudinal research showing that the indicator predates and 
prospectively predicts symptomatology, twin study anal-
yses demonstrating common genetic influences provide 
compelling evidence that the variable in question operates 
as an indicator of liability to that form of psychopathology 
(Figure 4).32 As an example, Hicks and colleagues33 used 
twin modeling to demonstrate that the association between 
blunted target-P3 amplitude and externalizing symptom-
atology was attributable entirely to genetic influences in 
common between the two (Figure 5). In sum, blunted 
target-P3 amplitude appears to be evident prior to the onset 
of externalizing psychopathology and shares heritable 
variance with externalizing problems.33 (Of note, target-P3 
and other executive function-related liability indicators 
are unlikely to be innately determined, but rather repre-
sent a product of genetic and environmental influences 
that give rise to a characteristically disinhibited cognitive- 
motivational style.15) These features suggest that blunted 
target-P3 response can be considered an indicator of liability 
for externalizing psychopathology (Figure 4).
Given that known liability factors tend to operate in a multi-
final manner—increasing risk for a variety of psychopathol-
ogies11—future research should establish whether liability 
factors as described here relate mainly to higher-order 
HiTOP dimensions, or in some cases relate selectively to 
a more specific form of psychopathology. For example, 
neuroimaging studies suggest that differentiable structural 
and functional correlates are observed at general versus 
more specific levels of the hierarchy,34,35 but it is not yet 
known whether these correlates function as liability indi-
cators. Similar to Barlow’s triple vulnerability model,36 
which posits that increasingly specific liabilities guide the 
expression of anxiety, transdiagnostic liabilities operating 
at higher levels of HiTOP (eg, the Externalizing super- 
spectrum) could be supplemented by more specific risk 
factors to produce particular signs and symptoms at the 
lower levels (eg, SPs).
Figure 4. Necessary attributes of liability factors as defined 
in the ontogenetic model. A) The candidate indicator of 
liability should be observable prior to the onset of psycho-
pathology and prospectively predict increases in relevant 
symptomatology. B) The association between the candidate 
indicator of liability and relevant symptomatology must be 
substantially attributable to shared genetic influences.
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Indexing liability using measures from different 
modalities: the psychoneurometric approach
One promising approach to improving the quantification 
of liability factors is to combine measures of a liability 
construct from different response modalities (eg, self- or 
other report, neural reactivity, task performance; Figure 3) 
into a multi-method “psychoneurometric” composite.6,37,38 
For example, liability for externalizing problems can be 
operationalized by combining scores on one or more 
questionnaire measures of disinhibition (ie, assessing 
tendencies to act in impulsive-irresponsible ways) with 
one or more variants of P3 brain response.38 This approach 
to quantifying externalizing liability is advantageous 
compared with a purely questionnaire-based measure 
because twin research demonstrates that a larger portion 
of the composite’s predictive association with external-
izing problems can be attributed to shared genetic vari-
ance.32 The reason is that the variance in common between 
scale-assessed disinhibition and externalizing problems 
reflects overlap in terms of environmental as well as 
genetic influences, whereas the variance in common 
between P3 brain response and externalizing problems 
reflects mainly overlapping genetic influences33,39 (Figure 
5). Prospective-longitudinal research could be undertaken 
to confirm that dispositional characteristics quantified in 
this manner predate manifest symptomatology and persist 
Figure 5. Visual representation of findings from twin studies of liability for externalizing. A) The observed association  
(r ~ -.2) between blunted target-P3 response and increased number of externalizing symptoms appears to reflect mostly 
shared genetic influences.33 B) The observed association (r ~ .6) between higher scores on a scale measure of trait disinhibition 
(ie, dispositional proneness to impulsive, irresponsible behavior) and increased number of externalizing symptoms appears  
to reflect both genetic and non-genetic influences.39 C) The observed association (r ~ -.2) between higher scores on a scale 
measure of trait disinhibition and blunted target-P3 response appears to reflect mostly shared genetic influences.39  
D) The observed association between a “psychoneurometric” (PNM) factor—computed by aggregating disinhibition-scale 
scores with P3-response measures32,38—and number of externalizing symptoms (r ~ .5) appears to reflect mostly shared genetic 
influences.32 The latter finding suggests that combining indicators of externalizing proneness from different measurement 
modalities (eg, questionnaire and brain response) may provide a purer index of liability than a questionnaire measure alone, 
and—as indicated by the greater overlap between ovals in D)—capture a larger portion of heritable variance in externalizing 
symptomatology than electrocortical responses alone.32,33
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through remission and relapse, as would be expected of 
liability factors (Figure 4).
The role of the environment
The progression from latent liability to manifest psychopa-
thology depends importantly on environmental influences. 
For example, genetic predispositions appear to exert greater 
influence on SPs among adolescents 
who associate with alcohol-using 
peer groups,40 an example of gene 
x environment interaction. In other 
words, the contribution of liability 
tends to be amplified in a develop-
mental context that is conducive 
to psychopathological expression. 
Moreover, an individual’s level of 
exposure to adverse environments 
can be predicted by genetic liability 
factors, a phenomenon known as 
gene-environment correlation. For example, individuals 
exhibiting weak inhibitory control—a heritable liability 
factor—appear more likely to self-select environments that 
lead to easier drug access, such as deviant peer groups.41 
Moreover, upon initiating substance use, an individual’s 
overestimation of their peers’ drug use predicts cogni-
tive and physiological changes associated with a worse 
trajectory.42,43 Overall, the cascading associations between 
liability and environment promote the emergence of psycho-
pathology.
Current symptomatology and concomitant 
neural indicators
Neural indicators of liability, as described above, predate 
the emergence of clinical symptoms and are likely to 
remain stable over the course of the illness. In contrast, as 
psychopathology first arises and fluctuates in severity over 
time, other neurobiological indicators are likely to follow 
a temporal course that parallels symptom changes. Such 
concomitant indicators are part and parcel of the psycho-
pathology itself (ie, disease-related dysfunction), as they 
accompany the presence of and changes in subjective 
experience and observed behavior patterns. Importantly, 
HiTOP-aligned symptom dimensions allow for the precise 
delineation of longitudinal relations between self- or other-
rated symptoms and neural features, in ways that traditional 
diagnostic categories cannot. Small changes in expression of 
HiTOP dimensions over time, regardless of their proximity 
to arbitrary DSM diagnostic thresholds, could be linked to 
modest within-person changes in neural response, whereas 
studies using diagnostic categories would offer far less 
precision in identifying such associations. An example of 
a concomitant process pertaining to SPs is incentive sensi-
tization,44 wherein stimuli that become associated with 
substance-related reward over time 
(eg, a hypodermic needle) acquire 
potency as motivational cues (ie, 
become objects of “wanting”) sepa-
rate from the hedonic impact of the 
substance itself (“liking,” eg, high of 
heroin).45 This process is thought to 
contribute to the maintenance of SPs 
and proneness to relapse following 
cessation of use.44
Incentive sensitization to psychoac-
tive substances can be considered a concomitant indicator 
of SPs because it appears to (i) develop alongside SPs; and 
(ii) vary longitudinally with SP symptom severity. Evidence 
for these points comes from ERP research demonstrating 
variability in the neural responses to substance-related cues 
among individuals with varying severity of SPs, as well 
as longitudinal changes in these responses within SP-di-
agnosed individuals who experience recovery. One robust 
electrocortical indicator of incentive sensitization is the 
alcohol cue reactivity P3 response (ACR-P346-48), which is 
evoked by alcohol-related cues in the context of a larger 
visual categorization task. The ACR-P3 appears to capture 
incentive valuation (ie, degree of “wanting”) of alcohol 
and is greater in heavier-drinking individuals.46 Other ERP 
indicators of incentive sensitization appear to covary with 
the longitudinal course of SPs. For example, in one study 
of individuals treated for cocaine use disorder, increases 
from pre- to post-treatment in the late positive potential 
response to pleasant non-drug-related images were found to 
be associated with decreased craving of cocaine following 
treatment.49
Taken together, these findings suggest that neural indicators 
of incentive sensitization may covary with the severity of 
SPs, both across individuals and within the same subjects 
over time. Importantly, unlike a liability factor, incentive 
sensitization cannot occur in substance-naïve individuals, 
instead developing concomitantly with the emergence 
HiTOP provides an ideal  
platform for ontogenetic  
research, given its reliable, 
clearly organized, and  
structurally valid  
symptom dimensions
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of SPs. One benefit of identifying such indicators is that 
they can then be utilized as measures of within-subject 
change in psychopathology, including treatment-related 
improvements. Incorporating regular assessment of these 
indicators into treatment37,50 could be particularly helpful 
for syndromes characterized by low insight into one’s 
own symptoms, such as SPs, as a supplement to report-
based measures and behavioral tasks (eg, the drug-choice 
paradigm, in which subjects decide between viewing 
substance-related and -unrelated images51). Knowledge 
of concomitant neural indicators could also facilitate the 
development of novel interventions, such as neurofeedback 
training, that hold promise for ameliorating certain forms 
of psychopathology.50
Neural indicators that change concomitantly with symp-
tomatology can also shed light on the prospective course 
of psychopathology, perhaps because of their presumed 
proximity to an underlying neural mechanism. (Note that 
it is critical not to conflate observed differences between 
patient and healthy control groups on some neural measure 
with discovery of a mechanism underlying that form of 
psychopathology, given: [i] the abovementioned limitations 
of diagnostic-group research that HiTOP was designed to 
address, as well as [ii] the impossibility of making mech-
anistic inferences from cross-sectional, ontogeny-agnostic 
studies, particularly when relevant experimental work has 
not been performed.) For example, once an individual has 
accumulated experience with alcohol, ACR-P3 amplitude 
appears to prospectively predict increased engagement in 
heavy drinking46; this association may reflect the mecha-
nistic role of incentive sensitization in the transition from 
repeated alcohol use to alcohol dependence. Whereas neural 
indicators of liability are clinically useful for identifying 
individuals at increased risk for psychopathology prior to 
symptom onset, concomitant neural indicators may have 
distinct utility for predicting future course among those 
already experiencing psychopathology.
Complicating matters further, liability and concomitant 
processes likely interact, such that mechanisms promoting 
symptom maintenance and exacerbation are enhanced by 
dispositional risk factors. One example from the neuroim-
aging literature is that, as incentive sensitization increases, 
a growing imbalance between incentive reward and exec-
utive control brain networks seems to lead to increasingly 
compulsive drug-related urges.52 Although executive control 
network activation in part reflects externalizing-related 
liability, its interaction with other brain systems in the 
context of emerging incentive sensitization promotes further 
development of substance-related psychopathology. This 
type of interplay is important to consider in studies seeking 
to identify neurobiological indicators of psychopathology 
risk and expression.
Consequences of psychopathology
The final component of this ontogenetic framework consists 
of the lasting consequences of psychopathology, including 
neurobiological measures indicative of dysfunction 
caused by illness. In contrast to the concomitant indicators 
described above, neural indicators that do not abate with the 
remission of psychological symptoms are consistent with 
a “scar” resulting from the experience of mental illness.17 
Some of the most apparent consequences of psychopa-
thology are medical, such as liver failure resulting from 
chronic alcohol overuse, or esophageal damage following 
frequent purging behaviors in eating pathology. However, 
psychopathology can also have lasting impacts on many 
psychological domains, from cognitive ability and person-
ality to sensorimotor adaptations, and these effects are likely 
mediated by biological changes. Neural consequences of 
psychopathology play an important role in the ontogenetic 
pathway because they can be used to monitor the progres-
sion of an illness in terms of lasting effects on the brain, in 
the same way that medical tests can be used to quantify the 
progression of liver failure.
As discussed for liability factors, one critical tool for estab-
lishing a given neural indicator as a consequence of psycho-
pathology is longitudinal research. In contrast to liability 
indicators, which must be present prior to the onset of 
psychopathology and persist over the course of illness, and 
concomitant neural indicators, which must be present along-
side clinical symptoms, scarring becomes apparent only 
following symptom onset and must persist in the face of 
changes in clinical presentation. Studies examining such a 
progression are exceedingly rare, and none to our knowledge 
have used HiTOP-aligned symptom-dimension designs. In 
the psychosis field, research has suggested that individuals 
diagnosed with schizophrenia may experience greater brain 
tissue loss per year (-0.5%) than healthy controls (-0.2%), 
with inconsistent links between symptom fluctuations 
and the rate of neural degeneration.53,54 However, these 
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gray matter alterations may also be present in high-risk 
premorbid individuals,55,56 suggesting they are not solely 
a consequence of the experience of psychosis. The advent 
of large-scale longitudinal studies that include functional 
and/or structural neural data will be of enormous utility in 
the search for indicators of neural scarring, as premorbid 
brain data will be available for those who go on to develop 
psychopathology.
In addition to longitudinal studies, co-twin control anal-
yses provide another means for evaluating whether an indi-
vidual difference characteristic reflects liability for versus 
consequences of psychopathology. This approach involves 
comparing twins with differing levels of symptomatology 
on a characteristic of interest, controlling for genetic and 
shared environmental influences. Evidence from co-twin 
control studies suggests that central nervous system hyper-
arousal and resultant negative affectivity—as well as 
alterations in electrocortical dynamics related to response 
inhibition—occur as consequences of alcohol use, and 
that alcohol, cannabis, and tobacco use contribute caus-
ally to reduced ventral striatum functional connectivity.57,58 
Each of these indicators is strongly linked to external-
izing psychopathology, but they are also implicated in 
other syndromes; in contrast, as described above, gray 
matter decrements appear relatively unique to psychosis. It 
remains to be seen which neural indicators reflect scarring 
effects at differing levels of specificity within the HiTOP 
hierarchy.
Research on other spectra and future directions
Various report-, performance-, and physiology-based 
measures have been shown to relate to diverse forms of 
psychopathology, but it remains unclear whether the 
constructs assessed by such measures represent stable pre- 
existing liability factors, correlates of current psychopa-
thology, or lasting consequences of illness. Ongoing work 
on the ontogeny of mental illness will require comprehen-
sive, multimodal assessment as well as longitudinal studies 
with genetically informative samples (eg, twins and/or indi-
viduals providing genomic data).37
The topics discussed here are not unique to SPs, nor to the 
Externalizing super-spectrum. Neural indicators of liability 
have been described in relation to numerous other forms 
of psychopathology. For example, the reward positivity 
(“RewP”) brain-ERP response shows a consistent nega-
tive association with major depression and prospectively 
predicts increases in depressive symptomatology.59,60 Impor-
tantly, this brain-response measure appears to index prone-
ness to depression rather than neural dysfunction associated 
with current depressive symptomatology.61 Bolstering the 
case for liability status, reduced RewP response is present 
in unaffected family members of depressed individuals62 
and is observed even in preschool-aged depressed chil-
dren.63,64 The RewP is also beginning to be examined in 
relation to other forms of psychopathology involving reward 
system dysfunction, including SPs.65 Beyond the RewP, 
numerous studies demonstrate that neurobiological indica-
tors, including other ERP measures, can be used to index 
liability for a range of psychopathology, including—but 
not limited to—SPs. A limitation of work to date is that 
relatively few studies have utilized dimensional symptom 
measures, and none to our knowledge have explicitly exam-
ined higher-order spectra of psychopathology in relation to 
ERPs, apart from the externalizing-P3 literature described 
above. HiTOP provides an optimal platform for testing 
research questions of this kind. For example, the notion 
that neural indicators of liability might operate primarily 
at higher-order levels of the HiTOP model represents an 
important topic for future investigation.
In contrast to the growing literature on neural indicators of 
liability, relatively little dimensional work has been under-
taken to distinguish these from neurobiological indicators 
of current symptoms or lasting consequences for any of the 
HiTOP dimensions. Much more extensive longitudinal and 
dimensional work is needed to better understand the latter 
two elements of the ontogenetic pathway, with the goal of 
predicting the future course of clinical problems and moni-
toring disease- and treatment-related change using neural 
measures.37,50,66
Beyond the individual model elements we have emphasized 
(liability, current symptomatology, consequences) and our 
specific focus on neurobiological indicators, the ontogenetic 
framework proposed here is not unique to the SP literature, 
nor to explicitly HiTOP-aligned research: It complements 
and extends existing ontogenetic models of externalizing, 
bipolar, and thought disorders.67-69 For example, McGorry 
et al69 proposed a “clinical staging” model of psychosis, 
mania, and depression wherein signs and symptoms largely 
overlapped at the earliest stages but became increasingly 
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distinct during the progression to acute, severe symptom-
atology. In parallel, our model posits that factors driving 
symptom expression at early stages should not be studied 
in isolation (eg, mania versus control group), but rather in 
line with a hierarchical understanding of mental illness at 
the HiTOP spectrum or super-spectrum level. For purposes 
of early identification and intervention, time is better spent 
understanding liability processes contributing to the gener-
ation of disordered cognitive and behavioral patterns shared 
across syndromes (ie, at higher levels of HiTOP), rather than 
in any subgroup alone. Conversely, symptom expression at 
the last stage of McGorry’s model69 is highly differenti-
ated and would likely operate at the symptoms/components 
level of HiTOP, potentially driving consequences specific 
to psychotic symptom expression and not mania, or vice 
versa. Here, neural indicators of current symptomatology 
and, perhaps, lasting consequences would be expected to 
show specificity to a particular syndrome. As illustrated 
by the parallels with McGorry’s model,69 as well as with 
models of other forms of psychopathology,67,68 the HiTOP 
framework and this ontogenetic perspective can be applied 
to myriad psychopathological conditions.
Conclusion
The ontogenetic model we have described provides a 
framework for organizing existing knowledge and guiding 
continued research on the etiology, mechanisms, and conse-
quences of mental illness as represented in the HiTOP 
model. In particular, we have emphasized how neurobio-
logical measures can aid in this endeavor and the ways in 
which HiTOP provides an ideal platform for ontogenetic 
research, given its reliable, clearly organized, and structur-
ally valid symptom dimensions. With a greater knowledge 
of the distinct liability factors, concomitant indicators, and 
lasting consequences associated with particular symptom 
dimensions, mental health professionals will be better 
equipped to identify and intervene with at-risk individuals 
and monitor the progressive remediation and lasting conse-
quences of their psychopathology. n
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